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Background

The Placement of Aortic Transcatheter Valves (PARTNER) trial showed that among
high-risk patients with aortic stenosis, the 1-year survival rates are similar with transcatheter aortic-valve replacement (TAVR) and surgical replacement. However, longerterm follow-up is necessary to determine whether TAVR has prolonged benefits.
Methods

At 25 centers, we randomly assigned 699 high-risk patients with severe aortic stenosis
to undergo either surgical aortic-valve replacement or TAVR. All patients were followed for at least 2 years, with assessment of clinical outcomes and echocardiographic
evaluation.
Results

The rates of death from any cause were similar in the TAVR and surgery groups
(hazard ratio with TAVR, 0.90; 95% confidence interval [CI], 0.71 to 1.15; P = 0.41) and
at 2 years (Kaplan–Meier analysis) were 33.9% in the TAVR group and 35.0% in the
surgery group (P = 0.78). The frequency of all strokes during follow-up did not differ
significantly between the two groups (hazard ratio, 1.22; 95% CI, 0.67 to 2.23;
P = 0.52). At 30 days, strokes were more frequent with TAVR than with surgical replacement (4.6% vs. 2.4%, P = 0.12); subsequently, there were 8 additional strokes in
the TAVR group and 12 in the surgery group. Improvement in valve areas was similar
with TAVR and surgical replacement and was maintained for 2 years. Paravalvular
regurgitation was more frequent after TAVR (P<0.001), and even mild paravalvular
regurgitation was associated with increased late mortality (P<0.001).
Conclusions

A 2-year follow-up of patients in the PARTNER trial supports TAVR as an alternative
to surgery in high-risk patients. The two treatments were similar with respect to
mortality, reduction in symptoms, and improved valve hemodynamics, but paravalvular regurgitation was more frequent after TAVR and was associated with increased late mortality. (Funded by Edwards Lifesciences; ClinicalTrials.gov number,
NCT00530894.)
n engl j med 366;18
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Tr anscatheter vs. Surgical Aortic-Valve Replacement

A

ortic stenosis is associated with
high mortality after the appearance of cardiac symptoms.1 Nevertheless, many patients do not undergo surgical aortic-valve replacement owing to real or perceived increased risks
associated with surgery.2-5 Transcatheter aorticvalve replacement (TAVR) has emerged as an alternative therapy in high-risk patients with aortic
stenosis.6-10 Observational registries from various countries have reported 1-month and 1-year
outcomes after TAVR,11-14 but there are limited
long-term follow-up data.15
The Placement of Aortic Transcatheter Valves
(PARTNER) trial was a randomized trial comparing TAVR with standard-of-care therapies in highrisk patients with aortic stenosis. One-year mortality outcomes from PARTNER showed that TAVR
was superior to standard therapy in patients who
could not undergo surgery16 and was noninferior
to surgical replacement in high-risk patients who
could undergo surgery.17 However, longer-term
data are required to assess valve durability and
to monitor late clinical complications, before
TAVR is used more widely in clinical practice.
This report describes the 2-year (and longer) clinical outcomes and echocardiographic findings after
TAVR or surgical aortic-valve replacement in the
high-risk patients in the PARTNER trial who could
undergo surgery.

Me thods
Patients

formed through a small intercostal incision over
the left ventricular apex with the use of a dedicated delivery catheter and the same SAPIEN valve.
Heparin was administered during the procedure, and dual antiplatelet therapy (aspirin and
clopidogrel) was recommended for 6 months afterward. The outpatient regimen was frequently
modified by the treating physicians because of
increased bleeding risks.
Study Design and Oversight

The study design and data-management practices
have been described previously.16,17 A total of 699
patients from 25 sites were randomly assigned to
TAVR or surgical replacement. Patients assigned
to TAVR were treated by either the transfemoral or
transapical approach on the basis of whether peripheral arteries could accommodate the large
sheaths required (22 French for the 23-mm valve
and 24 French for the 26-mm valve). Patients who
were randomly assigned to surgical replacement
were stratified according to whether a transfemoral or transapical approach would have been used.
The study was designed and monitored by the
sponsor, Edwards Lifesciences, and the executive
committee, which included four interventional
cardiologists and four cardiac surgeons. The sponsor funded the study and participated in the selection and management of the sites, the collection of the data, and data monitoring. The first
author and members of the executive committee
had unrestricted access to the data after the database had been locked and prepared all drafts of
the manuscript; they attest to the completeness
and accuracy of the reported data and to the adherence of the study to the protocol (available with
the full text of this article at NEJM.org). The trial
was approved by the institutional review board
at each site. Written informed consent was obtained from all patients.

Patient selection for this cohort of the PARTNER
trial has been described previously.17 Inclusion criteria were severe symptomatic aortic stenosis (an
aortic-valve area ≤0.8 cm2 plus a peak velocity ≥4 m
per second or a mean valve gradient ≥40 mm Hg)
and high-risk status for surgical aortic-valve replacement, as determined by experienced surgeons.
Patients were considered to be at high surgical
risk if they had coexisting conditions that were Study End Points
associated with a risk of death of at least 15% by The prespecified primary end point of the PARTNER trial was all-cause mortality at 1 year for the
30 days after the operation.
pooled cohort. Prespecified secondary end points
Study Device and Procedure
included cardiovascular mortality, stroke, repeat
The SAPIEN heart-valve system (Edwards Life- hospitalization, acute kidney injury, vascular comsciences) and the TAVR procedure have been de- plications, bleeding events, and New York Heart
scribed previously.16,17 Most procedures were per- Association (NYHA) functional class. All patients
formed in a hybrid operating room with a fixed were followed for at least 2 years and had annual
fluoroscopic imaging system, while the patient was clinical visits and echocardiographic evaluations.
under general anesthesia, and with transesopha- Crossovers between the two treatment groups were
geal echocardiography. Transapical TAVR was per- not permitted. A clinical-events committee was
n engl j med 366;18

nejm.org

may 3, 2012

1687

The New England Journal of Medicine
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on May 18, 2014. For personal use only. No other uses without permission.
Copyright © 2012 Massachusetts Medical Society. All rights reserved.

The

n e w e ng l a n d j o u r na l

responsible for adjudicating all end points. Definitions of the end points are identical to those in
the original trial and have been reported elsewhere.16,17
Statistical Analysis

For data analyses, the intention-to-treat analysis
started at the time of randomization, and the astreated analysis started at the time of induction
of anesthesia in the procedure room. All clinical
outcomes were primarily analyzed with the use
of an intention-to-treat analysis, but the results
of as-treated analyses are also presented for comparison. All echocardiographic analyses were performed with the use of the as-treated data. Categorical variables were compared with the use of
Fisher’s exact test. Continuous variables, presented
as means ±SD, were compared with the use of
Student’s t-test. Survival curves for time-to-event
variables were constructed with the use of Kap
lan–Meier estimates based on all available data
and were compared with the use of the log-rank
test. To study the effect of risk factors on mortality, Cox proportional-hazards regression was performed. For the multivariable analyses, multiple
imputations were used to accommodate missing
baseline variables. The multivariable models included covariates with a P value of less than 0.20
in univariate analyses. An additional time-dependent covariate analysis was performed to test the
association of complications during TAVR or surgical replacement with subsequent mortality. All
statistical analyses were performed with the use
of SAS software, version 9.2.

R e sult s
Patients

In the randomized TAVR group, 244 patients had
acceptable vascular access and were treated by
means of the transfemoral approach, and the remaining 104 patients were treated by means of
the transapical approach. Surgical replacement
was performed in 351 patients. Figure 1 in the
Supplementary Appendix, available at NEJM.org,
shows the study-group assignments and followup. All patients were followed for at least 2 years
(median, 727 days; maximum, 1490 days). The
overall study population was elderly (mean age,
84.1±6.6 years), had severe cardiac symptoms
(94.1% had NYHA class III or IV status), and had
frequent coexisting conditions (75.5% had a his1688
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tory of coronary artery disease, 43.0% had a history of coronary-artery bypass surgery, 42.4% had
peripheral vascular disease, 43.3% had pulmonary disease, and 41.3% had diabetes). The TAVR
and surgery groups were generally well matched
with regard to baseline characteristics (Table 1
in the Supplementary Appendix), except for a
slightly higher incidence of renal dysfunction in
the TAVR group (creatinine level >2 mg per deciliter [177 µmol per liter]: 10.8%, as compared
with 6.4% in the surgery group; P = 0.04). The
mean Society of Thoracic Surgeons predicted risk
of death at 30 days was 11.8±3.4%.
Of the 699 study patients, 42 did not receive
the assigned therapy: 4 in the TAVR group and 38
in the surgery group.17 The main reasons for nontreatment were withdrawal from the study and
the patient’s decision not to undergo surgery (28
patients).
Mortality and Stroke

Outcomes at 30 days and 1 year have been described previously.17 For the duration of the trial,
there were no significant differences in survival
between the TAVR and surgery groups in either
the intention-to-treat analysis (hazard ratio with
TAVR, 0.90; 95% confidence interval [CI], 0.71 to
1.15; P = 0.41) or the as-treated analysis (hazard
ratio, 0.98; 95% CI, 0.76 to 1.25; P = 0.85) (Fig. 1).
Between 1 and 2 years, there were 32 additional
deaths in the TAVR group and 25 in the surgery
group. At 2 years, there were no significant differences in mortality from any cause between the
TAVR group (33.9%; 95% CI, 28.9 to 39.0) and
the surgery group (35.0%; 95% CI, 29.8 to 40.2;
P = 0.78) (Table 1). Cardiovascular mortality at
2 years was also similar in the TAVR and surgery
groups (21.4% [95% CI, 16.8 to 26.0] and 20.5%
[95% CI, 15.8 to 25.3], respectively; P = 0.80). Similarly, in the as-treated analysis, the TAVR and surgery groups did not differ significantly with respect to all-cause mortality (33.9% and 32.7%,
respectively; P = 0.75) or cardiovascular mortality
(20.8% and 18.5%, respectively; P = 0.50) (Table 2
in the Supplementary Appendix).
Between 1 and 2 years, eight strokes occurred
(four in the TAVR group and four in the surgery
group) and three transient ischemic attacks (two
in the TAVR group and one in the surgery group).
The frequency of all neurologic events (strokes and
transient ischemic attacks) at 2 years was higher
with TAVR than with surgical replacement (11.2%
nejm.org
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A Death from Any Cause, Intention-to-Treat Population

B Death from Any Cause, As-Treated Population
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Figure 1. Time-to-Event Curves for the Primary and Other Selected End Points.
Events were calculated with the use of Kaplan–Meier methods and compared with the use of a logrank test. TAVR denotes transcatheter
aorticvalve replacement.

vs. 6.5%, P = 0.05). However, there was no significant difference in the number of overall strokes
between the TAVR and surgery groups (hazard
ratio, 1.22; 95% CI, 0.67 to 2.23; P = 0.52) (Fig. 1).
After the early increased hazard of stroke in the
first 30 days associated with TAVR (4.6% with
TAVR vs. 2.4% with surgical replacement, P = 0.12),
there were 8 additional strokes in the TAVR group
and 12 in the surgery group, such that the total
number of strokes over the follow-up period (36
months) was 24 in the TAVR group and 20 in the
surgery group. The composite of the rate of death
from any cause or stroke did not differ significantly between the two treatment groups (hazard
ratio, 0.93; 95% CI, 0.73 to 1.18; P = 0.55) (Fig. 1);
at 2 years, the rate was 37.1% in the TAVR group
and 36.4% in the surgery group (P = 0.85).

n engl j med 366;18

Other Clinical Outcomes

Other clinical events are summarized in Table 1.
Major vascular complications and major bleeding
events were frequent procedure-related complications in the TAVR and surgery groups, respectively, but after 1 year, these events were uncommon and did not differ significantly between the
groups. No patients were treated with balloon aortic valvuloplasty or repeat TAVR between 1 and
2 years. Endocarditis was rare and occurred at a
similar rate in the two groups (1.5% in the TAVR
group and 1.0% in the surgery group, P = 0.61).
No patients in either group had structural valve
deterioration requiring surgical replacement during follow-up.
At 2 years, there was no significant difference
in the rate of repeat hospitalization between the
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Table 1. Clinical Outcomes at 1 Year and 2 Years with TAVR or Surgery (Intention-to-Treat Population).*
Outcome

1 Year
Surgery
(N = 351)

2 Years

TAVR
(N = 348)

P Value†

Surgery
(N = 351)

no. of patients (%)

TAVR
(N = 348)

P Value†

no. of patients (%)

Death
From any cause

89 (26.8)

84 (24.3)

0.45

114 (35.0)

116 (33.9)

0.78

From cardiovascular causes

40 (13.0)

47 (14.3)

0.63

59 (20.5)

67 (21.4)

0.80

51 (17.7)

59 (18.6)

0.78

60 (21.7)

74 (24.7)

0.41

125 (37.7)

121 (34.9)

0.45

152 (46.5)

159 (46.6)

0.99

All

13 (4.3)

28 (8.7)

0.03

18 (6.5)

34 (11.2)

0.05

Stroke

10 (3.2)

20 (6.0)

0.08

14 (4.9)

24 (7.7)

0.17

4 (1.5)

8 (2.6)

0.32

5 (2.0)

10 (3.6)

0.26

95 (28.6)

95 (27.4)

0.74

119 (36.4)

127 (37.1)

0.85

0.16

4 (1.5)

Repeat hospitalization‡
Death from any cause or repeat
hospitalization‡
Stroke or TIA§

TIA
Death from any cause or stroke
Myocardial infarction

2 (0.6)

0

0

0.05

Major vascular complication¶

13 (3.8)

39 (11.3)

<0.001

13 (3.8)

40 (11.6)

<0.001

Major bleeding‖

88 (26.7)

52 (15.7)

<0.001

95 (29.5)

60 (19.0)

0.002

3 (1.0)

2 (0.6)

0.63

3 (1.0)

4 (1.5)

0.61

Renal failure**

20 (6.5)

18 (5.4)

0.57

21 (6.9)

20 (6.2)

0.75

New pacemaker

16 (5.0)

21 (6.4)

0.44

19 (6.4)

23 (7.2)

0.69

Endocarditis

SVD requiring surgical replacement

0

0

0

0

* All percentages are Kaplan–Meier estimates at the specific time point and thus do not equal the number of patients
divided by the total number in the study group. SVD denotes structural valve deterioration, TAVR transcatheter aorticvalve replacement, and TIA transient ischemic attack.
† P values are for between-group comparisons of the frequency of the event at each time point.
‡ Repeat hospitalizations were included in the analysis if they were for symptoms of heart failure, angina, or syncope
due to aortic-valve disease that required aortic-valve intervention or intensified medical management.
§ Stroke was defined as a neurologic deficit lasting more than 24 hours or lasting less than 24 hours with a brain-imag
ing study showing infarction.
¶ Major vascular complications were defined as thoracic aortic dissection; access-site or access-related vascular injury
leading to death, the need for substantial blood transfusion (>3 units), or percutaneous or surgical intervention; and
distal embolization (noncerebral) from a vascular source requiring surgery or amputation or resulting in irreversible
end-organ damage.
‖ Major bleeding was defined as any episode of major internal or external bleeding that caused death, hospitalization,
or permanent injury or that necessitated the transfusion of at least 3 units of packed red cells or a pericardiocentesis
procedure.
** Renal failure was defined as any condition requiring the initiation of any dialysis.

TAVR and surgery groups (24.7% and 21.7%, respectively; P = 0.41). Among survivors at 2 years,
the mean NYHA class was similar in the TAVR
and surgery groups (1.72 and 1.70, P = 0.87), and
the majority of patients in both groups had NYHA
class I or II status (83.9% in the TAVR group and
85.2% in the surgery group). Clinical outcomes in
the subgroups of patients in whom a transfemoral or transapical approach was used are shown
in Tables 3 through 6 in the Supplementary Appendix.

1690
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Predictors of Mortality

Predictors of mortality for the overall trial cohort
as well as for each of the randomized groups are
presented in Table 2. Treatment assignment was
not a significant predictor of the risk of death.
The time-dependent effect of treatment complications on subsequent mortality was also evaluated. Strokes greatly increased the hazard of
death in both groups (TAVR: hazard ratio, 2.47;
95% CI, 1.42 to 4.30; P<0.001; surgery: hazard
ratio, 5.20; 95% CI, 3.07 to 8.80; P<0.001). Major
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Table 2. Multivariable Predictors of Mortality.*
Hazard Ratio
(95% CI)

Variable

P Value

Overall
TAVR group

0.89 (0.70–1.13)

0.34

Body-mass index†

0.96 (0.94–0.98)

<0.001

Liver disease‡

2.24 (1.30–4.00)

0.006

Mean gradient per increase of 10 mm Hg

0.89 (0.81–0.98)

0.02

STS risk score§

1.04 (1.01–1.08)

0.02

Moderate or severe mitral regurgitation at baseline

1.36 (1.02–1.82)

0.04

Body-mass index†

0.93 (0.90–0.97)

<0.001

Mean gradient per increase of 10 mm Hg

0.82 (0.72–0.94)

0.003

Creatinine level at baseline¶

1.06 (1.00–1.13)

0.04

Prior vascular surgery or stent

1.85 (1.01–3.39)

0.05

CABG

0.57 (0.40–0.82)

0.002

STS risk score§

1.07 (1.02–1.12)

0.004

Liver disease‡

2.59 (1.16–5.43)

0.02

Moderate or severe mitral regurgitation at baseline

1.77 (1.17–2.68)

0.006

TAVR

Surgery

* Unless otherwise indicated, the hazard ratio reflects the presence or absence of the variable. CABG denotes coronaryartery bypass grafting.
† For body-mass index (the weight in kilograms divided by the square of the height in meters), the hazard ratio reflects
an increase of 1.
‡ Liver disease indicates a history of any liver condition.
§ The Society of Thoracic Surgeons (STS) risk score predicts the 30-day risk of death (on a scale of 0% to 100%, with
higher scores indicating higher predicted risk). The hazard ratio reflects an increase of 1%.
¶ For creatinine level at baseline, the hazard ratio reflects an increase of 1 mg per deciliter.

bleeding also increased the hazard of death in
both groups (TAVR: hazard ratio, 2.11; 95% CI,
1.41 to 3.17; P<0.001; surgery: hazard ratio, 2.94;
95% CI, 2.08 to 4.15; P<0.001). Major vascular
complications affected survival only in the TAVR
group (hazard ratio, 1.71; 95% CI, 1.07 to 2.73;
P = 0.02).
Echocardiographic Findings

uation 2 years after TAVR, paravalvular aortic regurgitation remained unchanged in 46.2% of patients, was improved in 31.5%, and was worse in
22.4% (Table 7 in the Supplementary Appendix).
The presence of paravalvular or total aortic regurgitation (mild, moderate, or severe vs. none or
trace) after TAVR was associated with increased
late mortality (hazard ratio, 2.11; 95% CI, 1.43 to
3.10; P<0.001) (Fig. 3). The effect of aortic regurgitation on mortality was proportional to the severity of the regurgitation (Fig. 3), but even mild
aortic regurgitation was associated with an increased rate of late deaths.

The early hemodynamic improvements that were
seen with both surgical replacement and TAVR
were maintained at 2 years, with no significant
changes in valve areas or mean gradients (Fig. 2).
Moderate or severe paravalvular aortic regurgitation was more common after TAVR than after
Discussion
surgical replacement at both 1 and 2 years (7.0%
vs. 1.9% at 1 year, and 6.9% vs. 0.9% at 2 years; The salient findings from this 2-year analysis of
P<0.001 for both comparisons). Among the 143 the randomized PARTNER trial are as follows:
patients who underwent echocardiographic eval- mortality after TAVR remained similar to that
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Figure 2. Echocardiographic Findings.
Panel A shows the aortic-valve area in the as-treated population; betweengroup differences were significant at 30 days through 1 year. Panel B shows
the mean gradient in the as-treated population; between-group differences
were significant at 30 days and 1 year. Error bars represent 1 SD in both
panels.

after surgical replacement, stroke frequency was
similar in the surgery and TAVR groups after
30 days, periprocedural complications (strokes,
major bleeding, and major vascular events) affected mortality after TAVR or surgical replacement;
aortic regurgitation (even mild) after TAVR was
associated with increased long-term mortality, and
valve performance in the TAVR group was maintained during follow-up and was similar to that
in the surgery group.
Early (30-day) mortality after TAVR has decreased to approximately 5% in several recent
studies, probably because of a combination of improvements in patient selection, procedural tech1692
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niques, and device technologies.12,14,16-18 However, 1- and 2-year mortality rates have remained
above 20% and 30%, respectively,11,15,19,20 raising a concern that TAVR may be associated with
important late complications. The results from
the PARTNER trial reveal similarly high mortality at 2 years with TAVR and with surgical replacement, indicating that coexisting conditions
play a role in late mortality. The multivariable
analysis from the combined TAVR and surgery
groups affirms the importance of coexisting conditions, because the STS risk score was a significant predictor of mortality at 2 years. Although
the STS score was designed to predict 30-day mortality after surgical replacement,21 many of the
baseline characteristics of the patients are also
likely contributors to late mortality.
The 30-day and 1-year PARTNER results raised
concern that TAVR was responsible for increased
early and, possibly, late strokes.16,17 The differences in stroke frequencies appeared in the first
few days or weeks after TAVR, presumably owing
to increased liberation of atherothrombotic debris
(from the valve or aorta), causing embolic ische
mic strokes. After this initial period, there is no
evidence of higher stroke rates in either group,
suggesting that the constant hazard of late strokes
in these elderly high-risk patients is unrelated to
the mode of valve-replacement therapy. The preferred anticoagulation regimen (early and late) for
patients after TAVR has not been determined.22
Early experiences with new cerebral filters23 suggest the frequent appearance of captured atherothrombotic material after TAVR, but careful
clinical studies with these new devices are just
beginning.
The current study shows stable gradients and
unchanged valve areas with the SAPIEN valve at
2 years. Nevertheless, structural valve deterioration
is well known with surgical bioprostheses, and
definitive assessments of valve durability will require much longer follow-up.24-26
A design limitation of transcatheter aortic
valves has been paravalvular regurgitation, which
results from incomplete circumferential apposition of the prosthesis with the annulus. Several
reports have indicated a relation between paravalvular regurgitation and mortality, but the certainty of these findings has been limited by the
lack of standardization of methods to assess aortic regurgitation.11,12,27,28 In our study, semiquantitative measures of aortic-regurgitation severity
were evaluated in an echocardiography core labonejm.org

may 3, 2012

The New England Journal of Medicine
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on May 18, 2014. For personal use only. No other uses without permission.
Copyright © 2012 Massachusetts Medical Society. All rights reserved.

Tr anscatheter vs. Surgical Aortic-Valve Replacement

A Severity of Paravalvular Leak: None or Trace versus Mild to Severe

60

Hazard ratio, 2.11 (95% CI, 1.43–3.10)
P<0.001 by log-rank test

50

Mild to severe

40
30

None or trace

20
10
0

0

6

12

18

24

to Severe

30

Death from Any Cause (%)

Death from Any Cause (%)

60

B Severity of Paravalvular Leak: None or Trace, Mild, or Moderate

30
20

None or trace

10
0

6

12

Months after Implantation

18

24

30

36

39
21
5

15
10
2

Months after Implantation

No. at Risk

No. at Risk

None or trace 158
Mild to severe 160

142
134

134
112

121
101

84
64

39
26

15
12

C Severity of Total Aortic Regurgitation: None or Trace versus Mild
60

60

Death from Any Cause (%)

Mild to severe

40
30

None or trace

20
10
0

0

6

12

18

24

30

142
115
19

121
86
15

84
51
13

50

Mild

Moderate
to severe

40
30

None or trace

20
10
0

36

P<0.001 by log-rank test

0

6

Months after Implantation

12

18

24

30

36

29
31
6

10
15
2

Months after Implantation

No. at Risk
None or trace 125
Mild to severe 196

134
95
17

or Moderate to Severe

Hazard ratio, 1.75 (95% CI, 1.17–2.61)
P=0.006 by log-rank test

50

None or trace 158
Mild
136
Moderate to 24
severe

D Severity of Total Aortic Regurgitation: None or Trace, Mild,

to Severe

Death from Any Cause (%)

Mild

Moderate
to severe

40

0

36

P<0.001 by log-rank test

50

No. at Risk
117
161

108
140

95
128

64
85

29
37

10
17

None or trace 125
Mild
162
Moderate to 34
severe

117
136
25

108
118
22

95
109
19

64
70
15

Figure 3. Relation of Aortic Regurgitation to All-Cause Mortality in the TAVR As-Treated Population.
Events were calculated with the use of Kaplan–Meier methods.

ratory; these assessments indicated a low frequency of moderate or severe paravalvular aortic
regurgitation (approximately 10%). Paravalvular
aortic regurgitation remained stable without significant worsening during follow-up. Nevertheless, even mild paravalvular (or total) aortic regurgitation (occurring in approximately 40% of
patients) was associated with increased late mortality (Fig. 3). Conversely, the absence of paravalvular aortic regurgitation or only trace regurgitation was associated with lower mortality in the
TAVR group.
These findings provide an important target
for improving outcomes after TAVR in the future.
The factors that underlie paravalvular aortic ren engl j med 366;18

gurgitation include the ratio of the transcathetervalve size to the size of the annulus, the position
of the prosthetic valve, and the pattern of calcification in the native valve.29-32 In the PARTNER
trial, the valve cover index,32 defined as 100 ×
[(valve prosthesis diameter − annulus diameter) ÷
valve prosthesis diameter], was lower in patients
with paravalvular aortic regurgitation, implicating systematic valve undersizing as an important
causative factor. Recently, the routine use of threedimensional imaging techniques has improved
annulus sizing, resulting in better selection of
properly sized valves.33-37 In addition, the selective use of post-TAVR dilation of the transcatheter
valve with slightly larger balloons may reduce imnejm.org
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mediate paravalvular aortic regurgitation during
TAVR, but the risks of aortic rupture, increased
central aortic regurgitation, and increased embolic
events must be considered. Future generations of
TAVR devices with improved subannular fixation designs or external space-filling materials
may also reduce incomplete apposition.
Several study limitations should be acknowledged. First, patients frequently declined surgery
after random assignment to surgical replacement,
resulting in a higher proportion of patients in the
surgery group who did not receive the assigned
treatment. Nonetheless, there were no significant
differences in clinical outcomes between the intention-to-treat cohort and the as-treated cohort.
Second, stroke assessments were limited, since
neurologic assessments were not mandated, modified Rankin scores were not used to determine
clinical disability, and documentation of atrial fibrillation episodes and anticoagulation regimens
was not complete. Third, the small number of patients in whom the transapical approach was
used and the differences in baseline characteristics make a comparison of the transfemoral
and transapical subgroups unreliable. Finally,
this study represented the initial experience with
TAVR at most of the sites, with the use of a
first-generation device. Multiple reports suggest
that subsequent device generations and increased
operator experience with TAVR may improve outcomes.18,38-40
In conclusion, this 2-year follow-up of patients
in the PARTNER trial supports the use of TAVR
as an alternative to surgery in selected high-risk
patients with aortic stenosis. The two treatments
were similar with respect to mortality, reduction
in cardiac symptoms, and improved valve hemodynamics. The early increase in the risk of stroke
with TAVR was attenuated over time. A new, important observation was the association of para-

of
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valvular regurgitation after TAVR with late mortality. Work now should be directed toward
reducing paravalvular aortic regurgitation with
improved device designs, techniques for more precise valve sizing and positioning, and judicious
use of post-TAVR dilation.
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